EPIX icon

ESSA Pharma

1.63 USD
-0.03
1.81%
At close Mar 13, 4:00 PM EDT
After hours
1.61
-0.02
1.23%
1 day
-1.81%
5 days
-0.61%
1 month
-6.32%
3 months
-0.61%
6 months
-76.20%
Year to date
-10.93%
1 year
-81.97%
5 years
-63.53%
10 years
-99.14%
 

About: ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.

Employees: 35

0
Funds holding %
of 7,372 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

225% more call options, than puts

Call options by funds: $179K | Put options by funds: $55K

130% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 10

41% more funds holding

Funds holding: 32 [Q3] → 45 (+13) [Q4]

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

5.16% less ownership

Funds ownership: 79.11% [Q3] → 73.96% (-5.16%) [Q4]

72% less capital invested

Capital invested by funds: $213M [Q3] → $58.8M (-$154M) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for EPIX.

Financial journalist opinion

Based on 241 articles about EPIX published over the past 30 days

Neutral
Accesswire
11 hours ago
Lost Money on ESSA Pharma Inc.(EPIX)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=135878&wire=1 or contact Joseph E. Levi, Esq.
Lost Money on ESSA Pharma Inc.(EPIX)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
Neutral
PRNewsWire
11 hours ago
EPIX Deadline: EPIX Investors Have Opportunity to Lead ESSA Pharma Inc. Securities Fraud Lawsuit
NEW YORK , March 13, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ESSA Pharma Inc. (NASDAQ: EPIX) between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period"), of the important March 25, 2025 lead plaintiff deadline. So what: If you purchased ESSA Pharma securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
EPIX Deadline: EPIX Investors Have Opportunity to Lead ESSA Pharma Inc. Securities Fraud Lawsuit
Neutral
Accesswire
14 hours ago
March 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against EPIX
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=135834&wire=1 or contact Joseph E. Levi, Esq.
March 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against EPIX
Neutral
GlobeNewsWire
14 hours ago
ESSA Pharma Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. March 25, 2025 Deadline to file Lead Plaintiff Motion
Investors can contact the law firm at no cost to learn more about recovering their losses
ESSA Pharma Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. March 25, 2025 Deadline to file Lead Plaintiff Motion
Neutral
GlobeNewsWire
17 hours ago
EPIX LAWSUIT ALERT: Levi & Korsinsky Notifies ESSA Pharma Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in ESSA Pharma Inc. ("ESSA Pharma Inc." or the "Company") (NASDAQ: EPIX) of a class action securities lawsuit.
EPIX LAWSUIT ALERT: Levi & Korsinsky Notifies ESSA Pharma Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Neutral
Accesswire
18 hours ago
EPIX LAWSUIT ALERT: Levi & Korsinsky Notifies ESSA Pharma Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=135780&wire=1 or contact Joseph E. Levi, Esq.
EPIX LAWSUIT ALERT: Levi & Korsinsky Notifies ESSA Pharma Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Neutral
Accesswire
19 hours ago
ESSA Pharma Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=135755&wire=1 or contact Joseph E. Levi, Esq.
ESSA Pharma Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX
Neutral
Accesswire
20 hours ago
EPIX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ESSA Pharma Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:EPIX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period").
EPIX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ESSA Pharma Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Neutral
Accesswire
20 hours ago
ESSA Pharma Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - EPIX
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=135743&wire=1 or contact Joseph E. Levi, Esq.
ESSA Pharma Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - EPIX
Neutral
Accesswire
20 hours ago
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against ESSA Pharma Inc. and Certain Officers - EPIX
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX) and certain officers. The class action, filed in the United States District Court for the Eastern District of Wisconsin, and docketed under 25-cv-00124, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against ESSA Pharma Inc. and Certain Officers - EPIX
Charts implemented using Lightweight Charts™